Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer

    Cancer Categories
    • Lung
    Karmanos Trial ID
    • NRG-LU008
    NCT ID
    • NCT05624996
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator

    Objective:

    Primary Objectives:

    • To compare the overall survival in patients with stage II-IIIC inoperable nodepositive
      non-small cell lung cancer (NSCLC) after image guided, motion-managed
      conventional radiotherapy to the primary tumor and nodal metastases (Arm 1) or after
      image guided, motion-managed stereotactic body radiation therapy (SBRT) to the
      primary tumor followed by conventionally fractionated radiotherapy to nodal
      metastases (Arm 2) both given with concurrent platinum-based chemotherapy.
    • To compare progression-free survival between the experimental arm (Arm 2) and
      control arm (Arm 1).

    Secondary Objectives:

    • To compare objective response rate (as defined by RECIST v 1.1) between the
      experimental arm and control arm
    • To compare the rate of local control between the experimental arm and control arm
    • To compare patterns of failure (primary, locoregional, or distant) between the
      experimental arm and control arm
    • To compare changes in pulmonary function (FEV1 and DLCO assessed at
      randomization and at 6 and 12 months following completion of radiation therapy)
      between the experimental arm and control arm
    • To compare changes in quality of life and patient-reported outcomes assessed from
      pre-treatment to 3 months following radiation therapy of each treatment arm
    • To determine acute and late toxicity profiles of each treatment arm as measured by
      the CTCAEv5
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at McLaren Bay Region

    3140 W Campus Dr.
    Bay City, MI 48706
    Get Directions
    Phone: 989-667-2370

    Karmanos Cancer Institute at McLaren Clarkston

    5680 Bow Pointe Dr
    Clarkston, MI 48346
    Get Directions
    Phone: 248-922-6650

    Karmanos Cancer Institute at McLaren Flint

    4100 Beecher Rd
    Flint, MI 48532
    Get Directions
    Phone: 810-342-3800

    Karmanos Cancer Institute at McLaren Greater Lansing - Medical Oncology and Hematology

    3520 Forest Rd.
    Lansing, MI 48910
    Get Directions
    Phone: 517-975-9500

    Karmanos Cancer Institute at McLaren Lapeer Region

    1295 Barry Drive
    Lapeer, MI 48446
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at McLaren Macomb

    1080 Harrington Blvd
    Mount Clemens, MI 48043
    Get Directions
    Phone: 586-493-7510

    Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey

    560 W Mitchell St
    Petoskey, MI 49770
    Get Directions
    Phone: 231-487-3390

    Karmanos Cancer Institute at McLaren Port Huron

    1221 Pine Grove Ave
    Port Huron, MI 48060
    Get Directions
    Phone: 810-982-5200

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions